Immunopathological study of Egyptian Patients with Chronic HCV Infection, Role of α-defensin, RANTES, and TNF-α

Gamal Othman*, Ayman Elbaz*, Khaled Farid **
Ashraf Omar***Mohamed Arafa****
Departments of Medical Biochemistry*, Tropical Medicine**, Internal Medicine *** Pathology****, Mansoura Faculty of Medicine

ABSTRACT

Background: Hepatitis C virus infection and its associated liver inflammatory disease is a major global health problem affecting over 170 million people worldwide. Following viral infection, multiple pro-inflammatory mediators contribute to recruitment of immune cells to the liver and to the generation of an anti-viral immune response. Multiple recent publications mark chemokines and their receptors as key players in leukocyte recirculation through the inflamed liver. Furthermore, chemokines may also be involved in liver regeneration, fibrosis, and in malignant transformation, which is induced by the persistence of inflammation. The Aim of this Study: The present study aimed to measure serum TNF-α, RANTES and α-defensins levels in patients with chronic hepatitis C and to estimate their relation to HCV viremia as well as grade of liver inflammation and stage of fibrosis.

Materials and Methods: 40 patients with chronic HCV and 20 normal controls were tested for liver function tests (Albumin, ALT, AST, ALP, Bilirubin), prothrombin activity, FBS, creatinine, CBC, AFP, HCV RNA, RANTES, TNF-α and α-defensins. Results: There were significant increase of serum levels of α-Defensins, RANTES and TNF-α in patients with chronic HCV infection compared with control group (P<0.05). α-defensins and RANTES showed significant positive correlation with HCV RNA viral load, grade of activity and stage of fibrosis while TNF-α showed significant positive correlation with grade of activity and stage of fibrosis only. Conclusion: The high linear correlation of levels of α-Defensins, RANTES and TNF-α with stage of liver fibrosis and grade of activity makes the measurement of these peptides reliable markers to evaluate liver fibrosis stage. The effects of these peptides need further studies and researches on a wide scale to clarify their possible mechanisms.

INTRODUCTION

HCV is a major human pathogen, infecting more than 170 million individuals; approximately 70% of those infected become chronic carriers and are at severe risk of developing liver fibrosis and cirrhosis (1). Production of chemokines in the liver is likely to play a role in HCV infection, as infiltration of lymphocytes has been observed in concomitance with chronic disease (2). RANTES (regulated upon activation,
normal T cell expressed and secreted) is a member of the chemokine family of chemotactic properties for T lymphocytes, monocytes, induced by some viruses and stimulates the host immune response to viral infections (3).

Inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), are integral part of inflammation in chronic hepatitis C infection. TNF-α and both types of circulating soluble TNF receptors (sTNFR) were not only increased in HCV-infected patients compared with controls, but sTNFR showed significant correlation with aminotransferase activities & the histological severity of inflammation (4).

Defensins are important components of the innate immunity, next to the complement pathway and phagocytes, are antimicrobial peptides, which play a pivotal role as key effectors of the immune system and act as endogenous antibiotics (5). Mammalian defensins are classified into three distinct sub-families due to the disulfide array: α-, β- und θ-defensins that exhibit a direct antimicrobial activity against a broad spectrum of microorganisms includes viruses (6).

The present study aimed to measure serum levels of α-Defensins, RANTES and TNF-α in patients with chronic hepatitis C and estimate their relation to HCV viremia as well as grade of liver inflammation and stage of fibrosis.

SUBJECTS & METHODS

Forty Egyptian patients with chronic hepatitis C virus (HCV) infection were recruited on their first examination at the Tropical Disease Unit Outpatient Clinic, Mansoura University Hospital. Twenty uninfected healthy subjects, matched for sex, and age, were recruited as a control group. All patients underwent a complete medical and laboratory evaluation including a liver ultrasound scan and biopsy.

The diagnosis of HCV infection was defined by typical biochemical and histological data and by detection of anti-HCV antibodies (Abbott AxSym HCV-3 and Ortho HCV 3.0 ELISA). Serum HCV-RNA was determined by real time PCR using Cobas Ampliprep/Cobas TaqMan, Roche Diagnostics, Pleasanton, USA, with detection limits >600 HCV-RNA IU/ml.

The entire study population was negative for other forms of viral hepatitis and for human immunodeficiency virus infection (HIV). Other conditions known to cause liver dysfunction were excluded on the basis of clinical evaluation and liver biopsy. The patients involved in this study stopped taking statogenic or antiviral drugs 6 months ago. None showed clinical or biochemical signs of advanced liver disease (their plasma prothrombin time and serum albumin were within normal ranges).

Blood samples were withdrawn from all subjects of the present study and each sample was divided into 3 aliquots; the first aliquot as EDTA anticoagulated blood for CBC, the second one as citrated plasma for measuring prothrombin activity and the third one was allowed to clot, centrifuged at 7000 rpm for 10 minutes to obtain serum which was
divided into two parts; the first part was used for measurement of liver function tests (Albumin, ALT, AST, ALP and Bilirubin), fasting blood glucose (FBG), creatinine and α fetoprotein and the second part was stored at –70°C until assayed for α-defensins, RANTES and TNF-α. 

RANTES and TNF-α were measured by sandwich ELISA technique using RANTES, TNF-α antigens ELISA kits purchased from Raytech ELISA kits (Helena laboratories, Beaumont, Texas). 

α-defensins were measured by sandwich ELISA technique using α-defensins antigens ELISA kits purchased from Hycult ELISA kits (Helena laboratories, Beaumont, Texas). 

Needle liver biopsy specimens were obtained from all patients for determination of stage of liver fibrosis and measurement of activity index with an 18-gauge needle with a minimum of 5 portal tracts and were routinely stained with hematoxylin–eosin stain. Histological analysis was independently performed by the pathologist without knowledge of any clinical and biological data except that patients had chronic HCV. 

Fibrosis were assessed according to the Metavir scoring system (7), on a five-point scale (F0=no fibrosis, F1=portal fibrosis without septa, F2=few septa, F3=numerous septa without cirrhosis, and F4=cirrhosis). Activity grading by the Metavir system (based on the intensity of periportal and lobular necroinflammation) were scored as follows: A0 = no histological activity, A1 = mild activity, A2 = moderate activity and A3 = severe activity. The presence of stage F0, F1 was termed “non significant liver fibrosis”; the presence of stage F2, F3, or F4 was termed “significant fibrosis”, whereas the term “advanced fibrosis” was reserved for stage F3 or F4. The presence of stage F4 was termed “liver cirrhosis”. 

Statistical analysis: Statistical analysis was done by using MedCalc program version 10.0.1 (8). Student t-test was used for quantitative data (mean ± SD) to compare any variable against control group. Spearman rank correlation coefficient was done to study the relation between variables. Odds ratio was done to calculate the ratio of the odds of the outcome in two groups. P ≤ 0.05 is considered significant.

RESULTS

Table (1) showed the differences between chronic HCV group and control group as regards biochemical parameters of liver function tests, CBC, creatinine, FBG, AFP and HCV-RNA viral load for evaluation of liver function and exclusion of other diseases such as diabetes mellitus, renal impairment and hepatic malignancy. This spreadsheet showed significant increase in ALT, AST, HCV_RNA viral load and significant decrease in platelets and prothrombin concentration among chronic HCV group when compared with control group.
Table (1): Biochemical parameters among chronic HCV group compared to control group (Median + range) with test of significance.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control N=20 Median (range)</th>
<th>HCV N=40 Median (range)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin (gm/dl)</td>
<td>4.3 (4.0-4.6)</td>
<td>4.25 (3.7-4.6)</td>
<td>0.288</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>21.5 (17-36)</td>
<td>52.5 (18-88.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>23.5 (17-37)</td>
<td>45 (12-91)</td>
<td>0.003</td>
</tr>
<tr>
<td>Bilirubin (mg/l)</td>
<td>0.75 (0.5-1.14)</td>
<td>0.89 (0.5-2.1)</td>
<td>0.121</td>
</tr>
<tr>
<td>Prothrombin Conc. (%)</td>
<td>96 (87-100)</td>
<td>84 (73-95)</td>
<td>0.001</td>
</tr>
<tr>
<td>AFP (ng/dl)</td>
<td>3.32 (0.9-6.3)</td>
<td>3.79 (0.9-17.6)</td>
<td>0.240</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.8 (0.6-1.3)</td>
<td>0.9 (0.6-1.3)</td>
<td>0.313</td>
</tr>
<tr>
<td>FBG (mg/dl)</td>
<td>93 (76-126)</td>
<td>95 (76-140)</td>
<td>0.473</td>
</tr>
<tr>
<td>Hb (gm/dl)</td>
<td>13.8 (12.5-16)</td>
<td>13.4 (11.7-16.6)</td>
<td>0.777</td>
</tr>
<tr>
<td>PLT (10^3 cells/L)</td>
<td>245 (160-330)</td>
<td>168 (107-296)</td>
<td>0.008</td>
</tr>
<tr>
<td>WBCs (10^3 cells/L)</td>
<td>6.1 (3.9 – 8.7)</td>
<td>5.6 (3.5 – 13.7)</td>
<td>0.879</td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>99.5 (51-194)</td>
<td>98 (53-198)</td>
<td>0.9653</td>
</tr>
<tr>
<td>HCV_RNA (IU/ml)</td>
<td>Below detection</td>
<td>415551.5 (15214-175095)</td>
<td>P&lt;0.0001</td>
</tr>
</tbody>
</table>

P≤ 0.05 is considered significant.

The present study showed significant increase of serum levels of α-Defensins, TNF-α, RANTES in patients with chronic HCV infection compared with control group (P <0.05) as shown in table 1.

Table (2): α-Defensins, TNF-α, RANTES among chronic HCV group compared to control group (Median + range) with test of significance.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control N=20 Median (range)</th>
<th>HCV N=40 Median (range)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-defensin (pg/ml)</td>
<td>2.72 (1.76-5.22)</td>
<td>9.08 (5.86-9.98)</td>
<td>0.023</td>
</tr>
<tr>
<td>RANTES (pg/ml)</td>
<td>21.56 (8.66-41.44)</td>
<td>77.62 (27-155)</td>
<td>0.0052</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>14.29 (6.68-28.56)</td>
<td>44.4850 (26.75-149.50)</td>
<td>0.012</td>
</tr>
</tbody>
</table>

P≤ 0.05 is considered significant.
There were significant positive correlation between α-Defensins and RANTES with HCV RNA viral load, grade of activity and stage of fibrosis while TNF-α showed significant positive correlation with grade of activity and stage of fibrosis only as shown in table (2) and this is supported by description of the relationship between two variables and to predict one variable from another by using linear regression between different measured parameters as shown in figure (2).

Table (3): Spearman correlation coefficient between biochemical parameters among HCV cases and HCV RNA viral load, grade of activity and stage of fibrosis

<table>
<thead>
<tr>
<th>Parameter</th>
<th>HCV RNA viral load</th>
<th>Activity grade</th>
<th>Stage of fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>α defensin (pg/ml)</td>
<td>r = 0.425</td>
<td>r = 0.341</td>
<td>r = 0.430</td>
</tr>
<tr>
<td></td>
<td>p = 0.017</td>
<td>p = 0.035</td>
<td>p = 0.015</td>
</tr>
<tr>
<td>RANTES (pg/ml)</td>
<td>r = 0.442</td>
<td>r = 0.507</td>
<td>r = 0.591</td>
</tr>
<tr>
<td></td>
<td>p = 0.010</td>
<td>p = 0.001</td>
<td>p = 0.0001</td>
</tr>
<tr>
<td>TNF-α(pg/ml)</td>
<td>r = 0.0648</td>
<td>r = 0.612</td>
<td>r = 0.612</td>
</tr>
<tr>
<td></td>
<td>P= 0.6911</td>
<td>P&lt;0.0001</td>
<td>P&lt;0.0001</td>
</tr>
</tbody>
</table>

P≤ 0.05 is considered significant.
Figure (2): scatter diagram and linear regression between each of α-defensin, RANTES, TNF-α with HCV RNA viral load, grade of activity and stage of fibrosis.
DISCUSSION

During HCV infection, chronic inflammation, regeneration and fibrosis are the key elements leading to liver dysfunction. Cytokines and chemokines are major regulators of these processes. Therefore, the outcome of HCV infection depends in part on a complex network of cytokine and chemokine interactions that orchestrate the innate and adaptive immune responses to HCV infection \(^\text{9}\).

There were significant increase of serum levels of α-Defensins, RANTES and TNF-α in patients with chronic HCV infection compared with control group (P <0.05). Also, α-Defensins and RANTES showed significant positive correlation with HCV RNA viral load, grade of activity and stage of fibrosis while TNF-α showed significant positive correlation with grade of activity and stage of fibrosis only.

These results were similar to the single previous research done by Aceti et al. \(^\text{10}\) who reported that HCV induces α-defensins expression. These results could be explained by its participation to tissue healing processes, as they have been reported to elicit fibroblast proliferation and deposition of extracellular matrix. Therefore, it is possible that, at physiologic concentrations, α-defensins might promote tissue repair, while at higher, pathologic concentrations, they might increase fibrogenesis and enhance a degenerative process in which functional hepatic tissue is replaced by fibrotic nonfunctional tissue.

Depending upon the concept of low number of researches on α-defensins in HCV, the results of the present study could support other comparative researches. During Chronic Periodontitis associated with HIV-1 infection, there is an increase in defensins, that known to have potent anti-HIV-1 activity \(^\text{11}\). In human peripheral blood, following the induction of lipopolysaccharide or heat-inactivated bacterial cells; α-defensins 1-3 genes were constitutively transcribed indicating their antimicrobial role \(^\text{12}\).

The findings of Chaly et al. \(^\text{13}\), suggested that neutrophil defensins have the potential to modulate the inflammatory responses through regulation of cytokine production and adhesion molecule expression.

Experimental evidence suggests that immune response factors, especially the pro-inflammatory cytokines, play an important role in liver injury induced by HBV and HCV \(^\text{14}\).

The results of Pawlak et al. \(^\text{15}\), suggested that the presence of viral hepatitis status and liver injury are novel determinants of increased oxidative stress, as well as of increased RANTES levels in uremic patients. Another study demonstrated that hepatitis C virus is capable of RANTES gene expression in both nonhepatic and hepatic cell lines \(^\text{16}\).

On contrary to the present study, Ruggieri1 et al. \(^\text{17}\), reported that HCV core protein has opposite effects on the expression of RANTES in different cell types in vitro, possibly reflecting a similar scenario in different microenvironments in vivo.
This result is analogous to Egyptian study done by Helaly and Abou Shamaa (18), who stated that TNF-α levels were dramatically elevated in HCV infected patients, in spite of their normal serum aminotransferases’ activities as compared with healthy control subjects. Although, serum levels of TNF-α were slightly elevated in viremic than non-viremic HCV infected patients, yet this difference did not reach the statistically significant level.

Increased concentrations and activity of plasma cytokines produced by monocytes, macrophages, and hepatocytes in patients with alcoholic liver diseases, correlate with the clinical course of liver diseases and are of prognostic value. Especially, high levels of circulating tumor necrosis factor (TNF-α) that have been found to correlate with increased mortality in alcoholic hepatitis. Moreover, hepatic RANTES was increased in patients with alcoholic hepatitis (19).

It was proved that RANTES was transcriptionally induced in human hepatoma cells by treatment with TNF-α via activation of NF-kappa B and p38 MAP kinase, presumably suggesting that TNF-α induced expression of RANTES plays an important role in cell-mediated liver injury in alcoholic liver diseases (20).

In addition, cytokines such as TNF-α were upregulated following infection. Furthermore, the vigorous immune response generated against HCV was associated with a dramatic change in the pattern of chemokine and chemokine receptor mRNA levels detected in the liver. The expression patterns of more than 16 chemokines and chemokine receptors were significantly attenuated during acute and chronic human HCV infection (21).

Both in patients with chronic HCV infection and in experimental models, TNF-α level in plasma, serum, and peripheral blood mononuclear cells are increased. Activation of the TNF-α system plays a central role in killing mechanisms of hepatitis C virus-specific human cytotoxic T cells (22).

Activation of TNF-α system has a pivotal role in the inflammatory process of chronic hepatitis C, and TNF-α levels correlate with the degree of inflammation (23).

It is not surprising that a number of cytokines have been involved in the outcome of HCV infection. In particular, the persistence of the virus and the response to antiviral therapy have been suggested to be associated with the production of inappropriate levels of TNF-α (24).

The α-defensins human neutrophil peptides (HNPs) have been reported to increase the production of TNF-α. Increased levels of proinflammatory factors (e.g. IL-1, TNF-α) at the site of microbial infection are likely to amplify local inflammatory responses. This might be further reinforced by the capacity of some human α-defensins to inhibit the production of immunosuppressive glucocorticoids by competing for the binding of adrenocorticotropic hormone to its receptor. Moreover, human α-defensins can enhance or suppress the activation of the classical pathway of complement in vitro by binding to solid-phase or fluid-phase complement C1q, respectively (25).
Conclusion: The high linear correlation of alpha-defensin levels, RANTES and TNF-α with stage of liver fibrosis and grade of activity makes the measurement of these peptides reliable markers to evaluate liver fibrosis stage. The effects of these peptides need further studies and researches on a wide scale to clarify their possible mechanisms.

REFERENCES


gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immunity 1: 386.

دراسة باثولوجية مناعيّة في مرضى الالتهاب الكبدى الفيروسى سي المزمن لدى المصريين ودور البروتين الدافعي الفأء المنشط الكيميائي رانتيس وعامل تتحر الورم الفأء

جمال عثمان ـ أمين الباز ـ خالد فريد ـ أشرف عمر حمد عزبة

أقسام الكيمياء الحيوية الطبية ـ الإماراض المتنوعة ـ الباطنة العامة ـ الباثولوجى ـ كلية الطب - جامعة المنصورة

هديد هذا البحث إلى قياس البروتين الدافعي الفأء المنشط الكيميائي رانتيس وعامل تتحر الورم الفأء في مرضى الالتهاب الكبدى الفيروسى سي لدى المصريين ومدى العلاقة بينهم وبين مدى تقيّس الدم، درجة التهاب الكبد والمرحل ليف الكبد.

وقد اشتملت هذه الدراسة على 100 رجل وسيدة، منهم 50 لا يعانون من مرض الالتهاب الكبدى الفيروسى سي ويتّلون المجموعة الضابطة للبحث، في حين اشتملت مجموعة المرضى على 50 رجل وسيدة يعانون من مرض الالتهاب الكبدى الفيروسى سي من المرضى المتزئدٍ على العيادة الخارجية للأمراض المزمنة في مستشفى المنصورة الجامعي. تمّ أخذ دم 10 بعد فترة تجريم 10 ساعات على ثلاث أنابيب انواعيّة تحتوي على مادة مانعة للتحتوج في الثلاجة تحتوي على ستات وثانيّة تحتوي على يوم قادام تم قياس كل من البروتين الدافعي الفأء، المنشط الكيميائي رانتيس، عامل تتحر الورم، وقائمة الفكيد، زمن ونشاط البروتورمونين، الكرياتنين، سكر صائم، الفايتوبروتين وتم تشخيص فيروسات التهاب الكبد الوبائي من خلال الكشف عن الفيروسات باثولوجية فيروس مزمن لدى المصريين للبحث.

كانت هناك زيادة كبيرة في مستويات البروتورمون الفأء المنشط الكيميائي رانتيس وعامل تتحر الورم الفأء في المرضى الذين يعانون من فيروس التهاب الكبد الوبائي المزمن مقارنةً مع المجموعة الضابطة للبحث، ووظر ارتباط إيجابي ذو دالة إحصائيّة بين البروتورمون الفأء المنشط الكيميائي رانتيس ومعامل تتحر الورم الفأء في مرضى الالتهاب الكبدى الفيروسى سي لدى المصريين مع تقيّس الدم، درجة التهاب الكبد والمرحل ليف الكبد. أمكن أن يكون معدل تتحر الورم الفأء مع تقيّس الدم من نتائج هذا البحث يمكن استنتاج وجود علاقة إيجابيّة بين البروتورمون الفأء المنشط الكيميائي رانتيس ومعامل تتحر الورم الفأء في مرضى الالتهاب الكبدى الفيروسى سي لدى المصريين مع درجة التهاب الكبد، والمرحل ليف الكبد، من الممكن استخدام هذه البروتورمونات كعلاجات عن مدى تقيّس الكبد، وهذا يتطلب المزيد من البحث والدراسة لهذه البروتورمونات على نطاق أوسع من الناس.